JAK3 JH2 ATP-binding site mutations efficiently suppressed ligand-independent STAT5 activation by JAK3 ALL-mutants R657Q, M511I in JH2, as well as L857Q in JH1 (Figure 4). Here, JAK3 is linked to acute lymphoblastic leukemia.